Methamphetamine and Crack Cocaine Scheduled Sunday 02/14/10 1 ...

Methamphetamine and Crack Cocaine Scheduled Sunday 02/14/10 1 ...

S. Alex Stalcup, M.D. New Leaf Treatment Center 251 Lafayette Circle, Suite 150 Lafayette, CA 94549 Tel: 925-284-5200 Fax: 925-284-5204 [email protected] Prescription Drug Abuse Opiate pain medications Benzodiazepine tranquilizers Prescription stimulants (Adderall, Ritalin)

Sleeping pills, muscle relaxants Percentage of State and Local Law Enforcement Agencies Reporting CPDs as Their Greatest Drug Threat, 2005-2009 Treatment Admissions / Local and State Primary Drugs of Abuse Washoe State Prescription Opiates Generic: Brand Name Codeine w/acetaminophen Hydrocodone:Vicodin, Lortab, Norco Hydromorphone: Dilaudid

Oxycodone: Percodan, OxyContin Morphine sulfate: MS Contin Fentanyl: Duragesic (transdermal), Actiq Non Tolerant 24 hr. dose 500 mg 20mg-60 mg 20 mg-60 mg 20 mg-60 mg 30 mg-60 mg 25 mcg-50 mcg Tolerant Users only Morphine sulfate: MS Contin Fentanyl: Duragesic (transdermal) Methadone: Methadose Buprenorphine: Suboxone, Subutex

Tolerant 24 hr. dose 60 mg-upward 75 mcg-300 mcg 60 mg-300 mg 6 mg-32 mg Neuroadaptation, Tolerance, and Withdrawal Neuroadaptation is the brains response to over stimulation from drugs. Sedation and stimulation (intoxication) are the result of excessive drug-specific effects on brain functions. Tolerance is the process by which the reward and pleasure centers of the brain adapt to high concentrations of pleasure

neurotransmitters. In direct response to overstimulation, the brain regions decrease in sensitivity and become unresponsive (deaf) to normal levels of stimulation. In addition to pleasure circuits each drug type affects other brain functions.. Other brain pathways overstimulated by drugs also neuroadapt and become under active, directly leading to anxiety, depression, and loss of energy. Once neuroadaptation develops (tolerance), there will always be Withdrawal symptoms that are the mirror image of the drug effects. Cessation of drug use leads to inversion of the high; sobriety becomes pleasureless, anxious, sleepless, and lacking energy Under unstimulated conditions (without drugs) there is profound interference with the ability to experience normal pleasure. When sober, the user experiences Craving: anhedonia, anxiety, anger, frustration. The pleasure system remains impaired for months to years, interfering with sobriety, learning, and impulse inhibition.

Definition of Addiction Compulsion: loss of control The user cant not do it s/he is compelled to use. Compulsion is not rational and is not planned. Continued use despite adverse consequences An addict is a person who uses even though s/he knows it is causing problems. Addiction is staged based on adverse consequences. Craving: daily symptom of the disease The user experiences intense psychological preoccupation with getting and using the drug. Craving is dysphoric, agitating and it feels very bad. Denial/hypofrontality: distortion of cognition caused by craving Under the pressure of intense craving, the user is temporarily blinded to the risks and consequences of using.

Causes of Craving in Addicts E W M S Environmental cues (Triggers) immediate, catastrophic, overwhelming craving stimulated by people, places, things associated with prior drug-use experiences

Drug Withdrawal inadequately treated or untreated Mental illness symptoms inadequately treated or untreated Stress equals craving Opiate Effects

Analgesia Euphoria Anxiolytic- calming Sleep Inducing Sensation of warmth Constipation Dry mucous membranes Pupils constrict (pinpoint pupils) Sedation/Sleepiness (nodding) Depresses respiration

Physical Dependence Tolerance Neuroadaptation forces the user to increase the dose to maintain the effect of the drug. Using an inadequate dose causes withdrawal: symptoms occur when the amount used is less than the tolerance level. Physical Dependence When the user stops the drug, physical illness results. Abstinence Syndrome Name of the illness caused by withdrawal symptoms. Core Principles in the Use of Opiates for Treatment of Chronic Pain: 1.

Detox from all sedative-hypnotic drugs, with meticulous attention to avoid all withdrawal symptoms 2. Substitute all opiates with sustained-release or long-acting opiates: MS Contin, methadone, suboxone 3. Titrate dose to optimum, the dose that relieves pain and relieves pain without sedation 4.

Avoid use of "breakthrough" medication Opiate Withdrawal Pain Dysphoria Anxiety

Insomnia Diarrhea Rhinorrhea Chills Pupils dilate Increases heart rate & blood pressure Kindling Overview of Buprenorphine (Suboxone and Subutex) Highly safe medication (acute & chronic dosing). Primary side effects: like other mu agonist opioids (e.g.,nausea, constipation) but may be less severe.

No evidence of significant disruption in cognitive or psychomotor performance with buprenorphine maintenance. No evidence of organ damage with chronic dosing. Use of Buprenorphine in the Pharmacologic Management of Opioid Dependence: A Curriculum of Physicians. (eds: Strain EC, Trhumble JG, Jara GB) CSAT. 2001 One Year Outcome of Opiate Treatment Kakko J, 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden_ a randomised, placebo-controlled trial. 2003 The Lancet 361 (9358) 662-668 Overall, the dismal outcome for

our controls reiterates the grave nature of heroin dependence, and shows the considerable health and social difficulties faced by our patients. Furthermore, the severity of problems in our patient sample is tragically emphasised by the 20% mortality in the controls over the course of a 1-year study. Opiate Progression Pills to the Needle Historically, untreated dependence on prescription opiates led to

a trajectory from Pills ingested orally Pills crushed and snorted or smoked Pills injected Heroin snorted or smoked Heroin used intravenously This progression develops over from 12 to 24 months

A 33-year follow-up of narcotics addicts . Special Problems in Former Opiate Addicts Persons previously addicted to opiates Have low pain tolerance because endogenous analgesic mechanisms are impaired. Will uncover their previous level of opiate tolerance over 4 - 6 weeks and require upward dosage titration over an extended time (despite years of abstinence). Require doses 2 to 4 times higher for analgesia than non-tolerant persons (due to high opiate tolerance).

Need slower, symptom-driven tapers to discontinue opiates. C I M Model Treatment Withdrawal Management PRINCIPLES SUBSTITUTION Calculate the dose equivalent per 24 hours Push medications to achieve symptom capture Maintain Diastolic BP <90 and Pulse <90 TAPER Decrease substitute medication in 10% increments Slow rate of taper to maintain Diastolic BP <90 and Pulse <90 Tremor free

Withdrawal Management Opiate Oral Dose Equivalents Buprenorphine (Suboxone) (sublingual) Hydrocodone (Vicodin) Methadone (Methadose) Morphine sulfate (immediate release) Morphine sulfate (MS Contin)

Oxycodone (Percodan) (Oxycontin) Propoxyphene (Darvon) 8 mg 10 - 20 mg 20 mg 30 mg 15 mg 10 - 20 mg 130 - 200 mg Adapted from Goodman and Gilman, 9th ed., page 535. Withdrawal Management

Opiate Substitution Query: time since last opiate use Query: all opiates used in past 7 days. Calculate client's usual 24 hour opiate dose. Query: prior withdrawal experience(s). Query: other drugs used: alcohol illicit drugs prescription medications

over-the-counter preparations Determine if client requires other detoxification Withdrawal Management Substitution Methodology Opiates Calculate Suboxone dose using opiate dose equivalents. Give first Suboxone dose (2 - 8 mg) when objective and clear signs of

withdrawal are evident. Record Pulse, BP, and withdrawal SX on Symptom Assessment sheet. Recheck Pulse & Blood Pressure after 90 minutes. Give 1/4 of estimated daily Suboxone dose when withdrawal symptoms reappear.

Give the remainder of Suboxone in divided doses every 6 - 8 hours. Withdrawal Management Completion of Substitution Phase Substitution is complete when the patient feels normal, and craving goes away. Persistence of insomnia, anxiety, pain, or depression indicate need for separate treatment of these symptoms (dual diagnosis). The patient is now ready for taper or for maintenance. Withdrawal Management Taper Phase There are two variables in tapering:

Dose: how much to taper Time: how often to taper Dose reductions are adjusted so that the patient does not re-enter withdrawal. If withdrawal symptoms develop during taper, return to previous effective dose, reduce amount of taper (dose) or lengthen the (time) interval. Do not continue until symptoms subside. Monitor Pulse and Blood Pressure daily Complete Symptom Assessment sheet daily. Adjust amount decreased and time between decreases to maintain symptom scores at 0-1 C I M Model Treatment Components of Treatment Initiation of Abstinence: Stopping Use

Drug Detoxification: Use of medications to control withdrawal symptoms Avoidance Strategies: Measures to protect the client from environmental cues Schedule: Establishing times for arising, mealtimes, and going to bed Mental Health Assessment and Treatment Relapse Prevention Drug Detoxification: Continued use of medications to control withdrawal Avoidance Strategies: Controlled re-entry to cue-rich environments Schedule: Adherence to a regular daily lifestyle -

HUNGRY ANGRY LONELY TIRED Three regularly spaced meals each day Separate feelings of anger from losing control of behavior One positive social contact per day minimum Daily practice of sleep hygiene Tools: Behaviors that dissipate craving Exercise Spiritual Practice Mental Health Treatment

Talk Peer Support Groups Counseling Having Fun C I M Model Treatment Relapse Prevention Workshop Principles Addicted persons relapse

because of craving. Craving has causes that can be predicted, recognized and analyzed. Craving can be managed with the use of program activities. Questions about Craving What is your craving score? What is the cause of your craving? Environmental cue Stress Drug withdrawal Mental health problems What will you do to take care of

yourself? Avoidance strategies Stress Management Tools Program activities REFERENCES Benowitz N. Neurobiology of nicotine addiction: implications for smoking cessation treatment. American Journal of Medicine. 121(4A) S3-S10 (2008). Bechara A. Decision making, impulse control and loss of willpower to resit

drugs: a neurocognitive perspective. Nature Neuroscience. 8:1458-63 (2005) Dackis C, OBrien C. Neurobiology of addiction: treatment and public policy ramifications. Nature Neuroscience. 8(11):1431-6 (2005). Nestler EJ, Malenka RC. The addicted brain. Scientific February 9, 2004. Stalcup SA, Christian D, Stalcup JA, Brown M Galloway GP. A treatment model for craving identification and management. Journal of Psychoactive Drugs. 38:235-44, 2006 Volkow ND, Fowler JS, Wang GJ. The addicted human brain: insights from imaging studies. Journal of Clinical Investigation. 111(10:1444-51 (2003). Weinberger DR, Elvevag B, Giedd JN. The adolescent brain: a work in progress. National Campaign to Prevent Teen Pregnancy. June 2005.

Recently Viewed Presentations

  • School of Education An evaluation of the collaboration

    School of Education An evaluation of the collaboration

    School of Education An evaluation of the collaboration between Mathematics and Science ITE tutors in developing teaching strategies to support their students with M ...
  • Forming Sector Partnerships One Door Many Paths June

    Forming Sector Partnerships One Door Many Paths June

    Presenters. Beth A. Brinly. Vice President, Workforce Innovation. Maher & Maher. ETHICS DISCLAIMER "This presentation reflects our (personal) views of the changes implied by WIOA and the actions a proactive workforce system professional may want to consider in preparing for...
  • Student Tennis Network September 2017 Content (45 mins)

    Student Tennis Network September 2017 Content (45 mins)

    Opportunity to engage with various British Tennis employees, and . gain insights into their roles. Mentoring phone calls 3 x year. Opportunity to develop your own employability skills through CV building training and completing an agreed tennis project
  • CSE 332 Data Abstractions: Algorithmic, Asymptotic, and Amortized

    CSE 332 Data Abstractions: Algorithmic, Asymptotic, and Amortized

    A valid proof is to find valid c and n. 0 When n=4, f=16 and g=16, so this is the crossing over point. We can then chose n 0 = 4, and c=1We also have infinitely many others choices for...
  • Speech Dynamics The Main Idea: At an abstract

    Speech Dynamics The Main Idea: At an abstract

    The phonetic structure of speech is an example of a discrete combinatorial system: morphemes and words are built by combining separate, independent, snap-together parts called phonemes or phonetic segments.. DNA works this way as well: Genes are built by combining...
  • Folie 1 - VSFK

    Folie 1 - VSFK

    Regionale Energieberatung 3600 Thun, T 033 225 22 90 Markus May Regionale Energieberatung Thun-Innertport, Kander-, Gürbe-, Aare- und Kiesental
  • Australian health libraries&#x27; contributions to hospital ...

    Australian health libraries' contributions to hospital ...

    Australian health libraries' contributions to hospital accreditation and the National Safety and Quality Health Services (NSQHS) Standards: results of the Health Libraries for National Standards (HeLiNS) research project
  • Aspiration Pneumonia - PuzzleVex

    Aspiration Pneumonia - PuzzleVex

    Aspiration Pneumonia Pathophysiology. Aspiration pneumonia is caused by the abnormal entry of secretions or substances into lower airway. These substances them provide an environment for bacteria to grow. There are four stages of aspiration pneumonia pathophysiology and they are as...